Are you registered? Register now to view Roche scientific information for HCPs!
You are here:
OAK: the largest Phase III cancer immunotherapy study in previously treated advanced NSCLC, regardless of PD-L1 expression1
Median OS was 13.8 months with TECENTRIQ vs 9.6 months with docetaxel
TECENTRIQ showed a favourable safety profile with low toxicity
1. TECENTRIQ prescribing information.
MatCode Approval No.: -1905-V2-3253
This website is intended for the use of healthcare professionals only,
Please approve that you are a healthcare professional in order to continue using this website.